posted
The company is undervalued..it is an innovative biotech company located in Research triangle park.NC..they have many patents with an annual rev of 27m..can be a buyout target above 1buck/share..o/s is only 39m with 36m float.
Icoria, Inc. is a biotechnology company dedicated to finding new ways of detecting and treating human disease. The Company uses its ability to analyze biological function at the level of gene expression, biochemical pathways and tissue structure to discover and validate biomarkers, drugs and drug targets. Icoria's business model provides opportunities to work with pharmaceutical, biotechnology, government and academic laboratories on a fee for service or collaborative basis, while it develops its own sets of products for internal development, or eventual out-licensing. The Company's internal programs focus on metabolic disorders (diabetes, obesity, among others) and the liver as a site of disease progression and drug action.
Icoria to Present at Fourth Annual Needham & Company Biotechnology Conference Monday May 23, 8:30 am ET
RESEARCH TRIANGLE PARK, N.C., May 23 /PRNewswire-FirstCall/ -- Icoria, Inc. (Nasdaq: ICOR - News) announced today that Chief Scientific Officer and Vice President, Research, Thomas J. Colatsky, Ph.D., will provide an overview of the Company at the upcoming Fourth Annual Needham & Company Biotechnology Conference at The New York Palace Hotel on Wednesday, May 25th at 4:30 PM ET. ADVERTISEMENT
About Icoria
Icoria, Inc. is a biotechnology company focused on the discovery of novel, multi-parameter biomarkers using its unique multi-platform approach. Icoria hopes to use these future biomarkers internally to develop multi-analyte diagnostics to define and grade pathology or disease state with a high level of specificity and sensitivity. Icoria also intends to use its technology to help its collaborators and customers develop better, safer drugs and diagnostics and to identify targets, leads and drug/diagnostic combinations for liver injury, metabolic disorders and cancer.
This press release contains forward-looking statements including, but not limited to, the Company's expectations for its healthcare based business model and its biomarker discovery platform. Such forward-looking statements are based on management's current expectations and are subject to a number of risks, factors and uncertainties that may cause actual results, events and performance to differ materially from those referred to in the forward-looking statements. These risks, factors and uncertainties include, but are not limited to, Icoria's ability to identify biomarkers, early stage of development, history of net losses, technological and product development uncertainties, reliance on research collaborations, uncertainty of additional funding and ability to protect its patents and proprietary rights. Certain of these and other risks are identified in Icoria's Quarterly Report on Form 10-Q for the period ended March 31, 2005, as amended, and its Annual Report on Form 10-K for the year ended December 31, 2004, both as filed with the Securities and Exchange Commission. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in our expectations, except as may be required by law.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
